NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting

RW McGilvray, RA Eagle, NFS Watson, A Al-Attar… - Clinical Cancer …, 2009 - AACR
RW McGilvray, RA Eagle, NFS Watson, A Al-Attar, G Ball, I Jafferji, J Trowsdale, LG Durrant
Clinical Cancer Research, 2009AACR
Purpose: NKG2D (natural killer group 2, member D) binds to cellular ligands of the MIC and
ULBP/RAET family. These ligands have restricted expression in normal tissue, but are
frequently expressed on primary tumors. The role of NKG2D ligands is thought to be
important in carcinogenesis but its prognostic effect has not been investigated in such a
large cohort. Experimental Design: In our study, 462 primary colorectal tumors were
screened for the expression of all MIC/ULBP/RAET proteins and NK cell infiltration. Tumor …
Abstract
Purpose: NKG2D (natural killer group 2, member D) binds to cellular ligands of the MIC and ULBP/RAET family. These ligands have restricted expression in normal tissue, but are frequently expressed on primary tumors. The role of NKG2D ligands is thought to be important in carcinogenesis but its prognostic effect has not been investigated in such a large cohort.
Experimental Design: In our study, 462 primary colorectal tumors were screened for the expression of all MIC/ULBP/RAET proteins and NK cell infiltration. Tumor microarray technology was used for the purpose of this investigation.
Results: NKG2D ligands were expressed by the majority of colorectal tumors; however, the level of expression varied considerably. High expression of MIC (68 versus 56 months) or RAET1G (74 versus 62 months) showed improved patient survival. Tumors expressing high levels of MIC and RAET1G showed improved survival of 77 months over tumors that expressed high levels of one ligand or low levels of both. High-level expression of all ligands was frequent in tumor-node-metastasis stage I tumors, but became progressively less frequent in stages II, III, and IV tumors. Expression of MIC was correlated with NK cellular infiltration.
Conclusion: The observations presented are consistent with an immunoediting mechanism that selects tumor cells that have lost or reduced their expression of NKG2D ligands. The combination of MIC and tumor-node-metastasis stage was found to be the strongest predictor of survival, splitting patients into eight groups and suggesting prognostic value in clinical assessment. Of particular interest were stage I patients with low expression of MIC who had a similar survival to stage III patients, and may be candidates for adjuvant therapy. (Clin Cancer Res 2009;15(22):69937002)
AACR